Home » pharmaceuticals industry » pharma » Department of Pharmaceuticals announces the Revamped Pharmaceuticals Technology Upgradation Assistance Scheme

Department of Pharmaceuticals announces the Revamped Pharmaceuticals Technology Upgradation Assistance Scheme

The Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers is announce the Revamped Pharmaceuticals Technology Upgradation Assistance (RPTUAS) Scheme. It is a significant step in government’s efforts to help upgrade the technological capabilities of our pharmaceutical industry and ensure its alignment with the global standards.

The approval of the revised Scheme follows a comprehensive review by the Scheme Steering Committee in light of the requirements of the revised Schedule-M of the Drugs and Cosmetics Rule, 1945 as issued by the Department of Health & Family Welfare on 28/12/2023. The revised guideline aims to support the pharmaceutical industry’s up-gradation to the Revised Schedule-M & WHO-GMP standards, enhancing the quality and safety of pharmaceutical products manufactured in our country.

Key Features of the Revised Scheme:

  • Broadened Eligibility Criteria: Reflecting a more inclusive approach, eligibility for the PTUAS has been expanded beyond Micro, Small and Medium Enterprises to include any pharmaceutical manufacturing unit with a turnover of less than 500 crores that requires technology and quality upgradation. Preference remains for MSMEs, supporting smaller players in achieving high-quality manufacturing standards.
  • Flexible Financing Options: The scheme introduces more flexible financing options, emphasizing subsidies on reimbursement basis, over traditional credit-linked approach. This flexibility is designed to diversify the financing options of the participating units, facilitating a more widespread adoption of the scheme.
  • Comprehensive Support for Compliance with New Standards: In alignment with revised Schedule-M and WHO-GMP standards, the scheme now supports a broader range of technological upgrades. Eligible activities include improvements such as HVAC systems, water and steam utilities, testing laboratories, stability chambers, clean room facilities, effluent treatment, waste management etc. ensuring comprehensive support for participating units.
  • Dynamic Incentive Structure: Pharmaceutical units with the following average turnover for the last three years will be eligible for incentive subject to a maximum of Rs. 1.00 crore per unit:-
Turnover Incentives
(i) Turnover less than Rs. 50.00 crore 20% of investment under eligible activities
(ii)Turnover from Rs. 50.00 crore to less than Rs. 250.00 crore 15% of investment under eligible activities;


(iii) Turnover from Rs. 250.00 crore to less than Rs. 500.00 crore 10% of investment under eligible activities.


  • State Government Scheme Integration: The revised scheme allows integration with state government schemes, enabling units to benefit from additional top-up assistance. This collaborative approach aims to maximize support for the pharmaceutical industry in their technology upgradation efforts.
  • Enhanced Verification Mechanism: The scheme introduces a robust verification mechanism through a Project Management Agency, ensuring transparency, accountability and the efficient allocation of resources.

Department of Pharmaceuticals is confident that reform in the PTUAS Scheme will contribute to pharmaceutical industry’s growth and compliance with global manufacturing standards. The revamped Scheme underscores government’s commitment to supporting the pharmaceutical industry which is critical to the nation’s health and well-being.

About IIPnews

Leave a Reply

Your email address will not be published. Required fields are marked *



Check Also

Pharmacopoeia Commission for Indian Medicine

The Government of India has established Pharmacopoeia Commission for Indian Medicine & Homoeopathy (PCIM&H), as ...

CCI releases key findings and observations on Market Study on Pharmaceuticals Sector in India

The Competition Commission of India (CCI) has released here today a report titled ‘Market Study on ...

Details of number of pharmaceutical drug manufacturers in States/UTs

As per Central Drugs Standard Control Organisation (CDSCO), the details of number of pharmaceutical drug ...

India to import 4,50,000 vials of Remdesivir

The Government of India has started importing the vital drug Remdesivir from other countries to ...

Approval accorded under PLI Scheme for Promotion of Domestic Manufacturing of critical Key Starting Materials (KSMs)/ Drug Intermediates and APIs in the country

With an objective to attain self-reliance and reduce import dependence in these critical Bulk Drugs ...

Union Chemicals & Fertilizers Minister inaugurates a four day Global Investors meet: India Pharma 2021 & India Medical Devices 2021

Union Chemicals and Fertilizers Minister Shri D V Sadananda Gowda inaugurated a four day Global ...

Cabinet approves Production Linked Incentive Scheme for Pharmaceuticals

The Union Cabinet, chaired by the Prime Minister, Shri Narendra Modi has approved Production Linked ...

Indian pharma market is expected to grow to US$ 130 billion by 2030: Shri DV Sadananda Gowda

Union Minister for Chemicals and Fertilizers, Mr D V Sadananda Gowda and Minister of State ...

Approval accorded under PLI Scheme for Promotion of Domestic Manufacturing of critical Key Starting Materials (KSMs)/ Drug Intermediates and APIs

The Applications of following companies, which have committed more than the minimum proposed annual production ...

Shri Sadananda Gowda launches 8 Nutraceutical-immunity boosting products under Pradhan Mantri Bhartiya Janaushadhi Priyojana for sale through Janaushadhi Kendras

Union Minister of Chemicals & Fertilizers Shri DV Sadananda Gowda launched here today 8 immunity ...

WP2Social Auto Publish Powered By : XYZScripts.com